Literature DB >> 15759047

Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy.

Anita Y M Chan1, Jason R B Dyck.   

Abstract

A necessary mediator of cardiac myocyte enlargement is protein synthesis, which is controlled, in part, by the highly energy-consuming process of peptide-chain elongation. Recently, AMP-activated protein kinase (AMPK), which is a key regulator of cellular energy homeostasis, has been shown to phosphorylate a number of enzymes involved in the control of protein synthesis. Since AMPK may inhibit protein synthesis via a number of different pathways, it is possible that AMPK is also a key regulator of cardiac hypertrophy. Recent advances linking AMPK and the energy status of the cell to the regulation of protein synthesis and (or) cardiac myocyte hypertrophy will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759047     DOI: 10.1139/y04-107

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  19 in total

Review 1.  The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism?

Authors:  T van Wessel; A de Haan; W J van der Laarse; R T Jaspers
Journal:  Eur J Appl Physiol       Date:  2010-07-03       Impact factor: 3.078

2.  AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.

Authors:  Junyu Ning; David R Clemmons
Journal:  Mol Endocrinol       Date:  2010-04-02

3.  Satellite cell activation and mTOR signaling pathway response to resistance and combined exercise in elite weight lifters.

Authors:  Chang Hyun Lim; Thien Suong Luu; Le Quy Phoung; Tae Seok Jeong; Chang Keun Kim
Journal:  Eur J Appl Physiol       Date:  2017-09-22       Impact factor: 3.078

4.  Isoform-selective 5'-AMP-activated protein kinase-dependent preconditioning mechanisms to prevent postischemic leukocyte-endothelial cell adhesive interactions.

Authors:  F Spencer Gaskin; Kazuhiro Kamada; Mozow Yusof Zuidema; Allan W Jones; Leona J Rubin; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

5.  Arctigenin alleviates ER stress via activating AMPK.

Authors:  Yuan Gu; Xiao-xiao Sun; Ji-ming Ye; Li He; Shou-sheng Yan; Hao-hao Zhang; Li-hong Hu; Jun-ying Yuan; Qiang Yu
Journal:  Acta Pharmacol Sin       Date:  2012-06-18       Impact factor: 6.150

6.  A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction.

Authors:  Sawako Shindo; Satoshi Numazawa; Takemi Yoshida
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

7.  Protein kinase A is a target for aging and the aging heart.

Authors:  Linda C Enns; Christina Pettan-Brewer; Warren Ladiges
Journal:  Aging (Albany NY)       Date:  2010-04       Impact factor: 5.682

8.  Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide.

Authors:  Miao Zhang; Yunzhou Dong; Jian Xu; Zhonglin Xie; Yong Wu; Ping Song; Melissa Guzman; Jiliang Wu; Ming-Hui Zou
Journal:  Circ Res       Date:  2007-12-06       Impact factor: 17.367

9.  Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction.

Authors:  Yasumasa Ikeda; Kaori Sato; David R Pimentel; Flora Sam; Reuben J Shaw; Jason R B Dyck; Kenneth Walsh
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

10.  Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.

Authors:  Neil L Spector; Yosef Yarden; Bradley Smith; Ljuba Lyass; Patricia Trusk; Karen Pry; Jason E Hill; Wenle Xia; Rony Seger; Sarah S Bacus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.